Brainsway (NASDAQ:BWAY) Upgraded to Buy at Wall Street Zen

Brainsway (NASDAQ:BWAY) was upgraded by investment analysts at Wall Street Zen from a “hold” rating to a “buy” rating in a research report issued on Saturday.

BWAY has been the subject of several other research reports. Weiss Ratings reiterated a “hold (c)” rating on shares of Brainsway in a research note on Monday. HC Wainwright lifted their price target on Brainsway from $18.00 to $24.00 and gave the stock a “buy” rating in a report on Monday. Finally, Northland Securities upped their price objective on Brainsway from $19.00 to $23.00 and gave the company an “outperform” rating in a research note on Wednesday, November 12th. Two analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $23.50.

Brainsway Trading Down 2.6%

Shares of Brainsway stock opened at $16.97 on Friday. The company has a market capitalization of $332.00 million, a P/E ratio of 56.57 and a beta of 1.22. The stock has a fifty day simple moving average of $16.18 and a 200 day simple moving average of $14.21. Brainsway has a 12-month low of $7.84 and a 12-month high of $18.17.

Brainsway (NASDAQ:BWAY) last posted its quarterly earnings data on Tuesday, November 11th. The company reported $0.08 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.11 by ($0.03). The firm had revenue of $13.51 million for the quarter, compared to analysts’ expectations of $13.04 million. Brainsway had a return on equity of 9.46% and a net margin of 12.73%. On average, analysts predict that Brainsway will post 0.08 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of BWAY. UBS Group AG boosted its stake in Brainsway by 2,028.6% in the 3rd quarter. UBS Group AG now owns 63,878 shares of the company’s stock worth $963,000 after purchasing an additional 60,877 shares during the period. Two Sigma Investments LP lifted its holdings in shares of Brainsway by 25.2% in the third quarter. Two Sigma Investments LP now owns 102,902 shares of the company’s stock worth $1,551,000 after buying an additional 20,706 shares in the last quarter. Y.D. More Investments Ltd bought a new position in shares of Brainsway in the third quarter valued at approximately $263,000. Millennium Management LLC boosted its position in shares of Brainsway by 69.6% in the third quarter. Millennium Management LLC now owns 39,841 shares of the company’s stock valued at $600,000 after acquiring an additional 16,354 shares during the period. Finally, Trexquant Investment LP purchased a new position in Brainsway during the first quarter valued at approximately $129,000. 30.11% of the stock is owned by institutional investors.

Brainsway Company Profile

BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases.